Background: Maintenance therapy is important in advanced/metastatic non-small cell lung
cancer (NSCLC). Erlotinib as switch maintenance following platinum-based chemotherapy …

Background Cyclin-dependent kinase 5 (CDK5) is an atypical CDK which plays a vital role
in several cancers via regulating migration and motility of cancer cells. However, the …

Background The benefit of maintenance therapy has been confirmed in patients with non-
progressing non-small cell lung cancer (NSCLC) after first-line therapy by many trials and …

Background: There have been several case–control studies to assess the relationship
between the transforming growth factor-β1 (TGF-β1) T+ 869C (rs1982073)/C-509T …

Background Although previous in vitro data have suggested a more radio-sensitive nature of
epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) cell …

Most lung cancers are diagnosed at fairly advanced stages due to limited clinical symptoms.
Platinum-based chemotherapy, either as single regimen or in combination with radiation, is …

Purpose Both gefitinib and pemetrexed maintenance were effective therapies for advanced
lung adenocarcinoma, but which is better is unclear. For patients with advanced lung …

Purpose Maintenance therapy is an effective treatment strategy for advanced non-small-cell
lung cancer (NSCLC). We aim to investigate whether age would affect the efficacy of …

Management for locally advanced non-small cell lung cancer (LANSCLC), which consists of
Stage IIIA and IIIB disease, has progressed throughout the decades. While overall survival …

The economic burden associated with the treatment of lung cancer is substantial. With the
introduction of targeted therapy and immunotherapy, treatment options for lung cancer …